Search results
Showing 706 to 720 of 1422 results for social care
Evidence-based recommendations on rimegepant (Vydura) for preventing migraine in adults.
The section of the NICE impact lung cancer report looking at how lung cancer is detected.
The NICE public health guidance development process (third edition) (PMG5)
The NICE public health guidance development process (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection
- 3 The guidance development processes
- 4 The role of stakeholders in the guidance development process
- 5 The role of the Public Health Advisory Committees (PHACs) in the development of public health guidance
- 6 The role of evidence providers
- 7 The role of the CPHE project team
- 8 Fieldwork
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
View recommendations for TA489Show all sections
Interim process and methods statement for bringing together NICE guidance (PMG47)
This interim process and methods statement sets out the general principles guiding NICE's approach to including NICE technology appraisal recommendations in guideline topic areas. It also describes what the key changes are to existing methods and processes
Show all sections
- Overview
- Introduction
- 1 Why we are bringing together NICE guidance
- 2 Process and methods for incorporating NICE technology appraisals into NICE guideline topic areas
- 3 Approach to further development of process and methods for bringing together NICE guidance
- 4 Updates to this interim process and methods statement
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Evidence-based recommendations on vortioxetine (Brintellix) for treating major depressive episodes in adults.
Specialist neonatal respiratory care for babies born preterm (QS193)
This quality standard covers neonatal respiratory support in hospital for babies born preterm (before 37 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
View quality statements for QS193Show all sections
Sections for QS193
- Quality statements
- Quality statement 1: Respiratory support soon after birth
- Quality statement 2: Minimally invasive administration of surfactant
- Quality statement 3: Invasive ventilation
- Quality statement 4: Oxygen saturation
- Quality statement 5: Involving parents and carers
- Update information
- About this quality standard
Position statement on use of the EQ-5D-5L value set for England (updated October 2019)
Our position on use of the EQ-5D-5L valuation set for England
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Show all sections
- 1 Introduction
- 2 Topic selection and scoping the guidance
- 3 Determining the evidence for review and consideration
- 4 Identifying the evidence
- 5 Reviewing the scientific evidence
- 6 Incorporating health economics
- 7 Developing recommendations
- Appendix A Conceptual framework for the work of the Centre for Public Health Excellence (CPHE)
This quality standard covers recognising, assessing and managing coeliac disease in adults, young people and children. It describes high-quality care in priority areas for improvement.
View quality statements for QS134Show all sections
Sections for QS134
- Quality statements
- Quality statement 1: Serological testing for coeliac disease
- Quality statement 2: Referral to a specialist
- Quality statement 3: Endoscopic intestinal biopsy
- Quality statement 4: Advice about a gluten-free diet
- Quality statement 5: Annual review
- Update information
- About this quality standard
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.